Dania Villarnovo1, Angela L McCleary-Wheeler, Kristy L Richards. 1. aDepartment of Biomedical Sciences bDepartment of Clinical Sciences, College of Veterinary Medicine, Cornell University, Ithaca cSandra and Edward Meyer Cancer Center dDivision of Hematology/Oncology, Weill Cornell Medicine, New York, New York, USA.
Abstract
PURPOSE OF REVIEW: Spontaneous lymphoma in pet dogs is increasingly recognized as an ideal model for studying the disease in humans and for developing new targeted therapeutics for patients. Increasing interest by funding agencies, the private sector, and multidisciplinary academic collaborations between different disciplines and sectors now enables large knowledge gaps to be addressed and provides additional proof-of-concept examples to showcase the significance of the canine model. RECENT FINDINGS: The current review addresses the rationale for a canine lymphoma model including the valuable role it can play in drug development, serving as a link between mouse xenograft models and human clinical trials and the infrastructure that is now in place to facilitate these studies. Research in this field has focused on filling in the gaps to make the canine lymphoma model more robust. These advances have included work on biomarkers, detection of minimal residual disease, expansion of genomic and proteomic data, and immunotherapy. SUMMARY: Incorporating pet dogs into the drug development pipeline can improve the efficiency and predictability of preclinical models and decrease the time and cost required for a therapeutic target to be translated into clinical benefit.
PURPOSE OF REVIEW: Spontaneous lymphoma in pet dogs is increasingly recognized as an ideal model for studying the disease in humans and for developing new targeted therapeutics for patients. Increasing interest by funding agencies, the private sector, and multidisciplinary academic collaborations between different disciplines and sectors now enables large knowledge gaps to be addressed and provides additional proof-of-concept examples to showcase the significance of the canine model. RECENT FINDINGS: The current review addresses the rationale for a canine lymphoma model including the valuable role it can play in drug development, serving as a link between mouse xenograft models and human clinical trials and the infrastructure that is now in place to facilitate these studies. Research in this field has focused on filling in the gaps to make the canine lymphoma model more robust. These advances have included work on biomarkers, detection of minimal residual disease, expansion of genomic and proteomic data, and immunotherapy. SUMMARY: Incorporating pet dogs into the drug development pipeline can improve the efficiency and predictability of preclinical models and decrease the time and cost required for a therapeutic target to be translated into clinical benefit.
Authors: A Poggi; B Miniscalco; E Morello; F Gattino; A Delaude; L Ferrero Poschetto; L Aresu; M E Gelain; V Martini; S Comazzi; F Riondato Journal: Vet Comp Oncol Date: 2016-01-21 Impact factor: 2.613
Authors: Manikhandan A V Mudaliar; Ross D Haggart; Gino Miele; Grant Sellar; Karen A L Tan; John R Goodlad; Elspeth Milne; David M Vail; Ilene Kurzman; Daniel Crowther; David J Argyle Journal: PLoS One Date: 2013-09-04 Impact factor: 3.240
Authors: Bonnie K Harrington; Heather L Gardner; Raquel Izumi; Ahmed Hamdy; Wayne Rothbaum; Kevin R Coombes; Todd Covey; Allard Kaptein; Michael Gulrajani; Bart Van Lith; Cecile Krejsa; Christopher C Coss; Duncan S Russell; Xiaoli Zhang; Bridget K Urie; Cheryl A London; John C Byrd; Amy J Johnson; William C Kisseberth Journal: PLoS One Date: 2016-07-19 Impact factor: 3.240
Authors: Sarah C Roode; Daniel Rotroff; Kristy L Richards; Peter Moore; Alison Motsinger-Reif; Yasuhiko Okamura; Takuya Mizuno; Hajime Tsujimoto; Steven E Suter; Matthew Breen Journal: BMC Vet Res Date: 2016-09-17 Impact factor: 2.741
Authors: Kelly R Hume; Skylar R Sylvester; Lucia Borlle; Cheryl E Balkman; Angela L McCleary-Wheeler; Mary Pulvino; Carla Casulo; Jiyong Zhao Journal: Front Vet Sci Date: 2018-02-26
Authors: Anna-Janina Behrens; Rebecca M Duke; Laudine Mc Petralia; David J Harvey; Sylvain Lehoux; Paula E Magnelli; Christopher H Taron; Jeremy M Foster Journal: Glycobiology Date: 2018-11-01 Impact factor: 4.313
Authors: Michelle R Goulart; Sabina I Hlavaty; Yu-Mei Chang; Gerry Polton; Anneliese Stell; James Perry; Ying Wu; Eshita Sharma; John Broxholme; Avery C Lee; Balazs Szladovits; Mark Turmaine; John Gribben; Dong Xia; Oliver A Garden Journal: Sci Rep Date: 2019-03-05 Impact factor: 4.379
Authors: Jason Chibuk; Andi Flory; Kristina M Kruglyak; Nicole Leibman; Alexis Nahama; Nilesh Dharajiya; Dirk van den Boom; Taylor J Jensen; Jeffrey S Friedman; M Richard Shen; Francisco Clemente-Vicario; Ilya Chorny; John A Tynan; Katherine M Lytle; Lauren E Holtvoigt; Muhammed Murtaza; Luis A Diaz; Dana W Y Tsui; Daniel S Grosu Journal: Front Vet Sci Date: 2021-03-23